Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Blood (2007) 110 (11): 1984.

https://doi.org/10.1182/blood.V110.11.1984.1984

Published: 2007

Journal Articles

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

Gaurav C. Parikh, MD, MPH (2nd Year), Rima M. Saliba, Ph.D., Amit Lahoti, MD, Chitra Hosing, MD, Floralyn Mendoza, BS, Suhail R. Qureshi, MD, Donna M. Weber, MD, BS, Michael Wang, MD, MS, Uday Popat, MD, Amin Alousi, MD, Richard E. Champlin, MD, Sergio A. Giralt, MD, Muzaffar H. Qazilbash, MD

Blood (2007) 110 (11): 5126.

https://doi.org/10.1182/blood.V110.11.5126.5126

Published: 2007

Journal Articles

A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima M. Saliba, PhD, Gaurav C. Parikh, MD, Chitra Hosing, MD, Floralyn Mendoza, BS, Donna M. Weber, MD, Michael Wang, MD, Sheeba K. Thomas, MD, Thuy S. Flosser, BS, Partow Kebriaei, MD, Uday Popat, MD, Amin M. Alousi, MD, Marcos de Lima, MD, Richard E. Champlin, MD, Sergio A. Giralt

Blood (2007) 110 (11): 3032.

https://doi.org/10.1182/blood.V110.11.3032.3032

Published: 2007

Journal Articles

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Sergio Giralt, MD, Rupi Thandi, MD, Muzaffar Qazilbash, MD, Floralyn Mendoza, BS, Eric Han, BS, Chitra Hosing, MD, Michael Wang, MD, Sheeba Thomas, MD, Raymond Alexanian, MD, Richard Champlin, MD, Donna Weber, MD

Blood (2007) 110 (11): 948.

https://doi.org/10.1182/blood.V110.11.948.948

Published: 2007

Journal Articles

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Michele Donato, MD, Ana Aleman, MD, Donna Weber, MD, Michael Wang, MD, Muzaffer Qazilbasch, MD, Marilyn Davis, R.N., Linda Roden, MD, Floralyn Mendoza, BS, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 1177.

https://doi.org/10.1182/blood.V106.11.1177.1177

Published: 2005

Journal Articles

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Erica Campagnaro, MD, Rima Saliba, Ph.D, Karen Anderson, Ph.D, Linda Roden, MD, Floralyn Mendoza, BS, Ana Aleman, MD, Charles Cleeland, Ph.D, Donna Weber, MD, Jane Brown, RN, Sergio Giralt, MD

Blood (2005) 106 (11): 1771.

https://doi.org/10.1182/blood.V106.11.1771.1771

Published: 2005

Journal Articles

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Anna Christoforidou, MD, Patricia Williams, RN, Linda Roden, MD, Ana Aleman, MD, Donna Weber, MD, Floralyn Mendoza, BS, Donald Podoloff, MD, Hazel Breitz, MD, Raymond Alexanian, MD, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 426.

https://doi.org/10.1182/blood.V106.11.426.426

Published: 2005

NARROW

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Email alerts

ASH Publications

American Society of Hematology

Pre Transplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT).

Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.

A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.

Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only